Get started

Financials · VIR

Vir Biotechnology Inc. (VIR) financials

For the twelve months ended Sep 30, 2026, Vir Biotechnology Inc. reported $302.80M of revenue and -$184.79M of net income.

Revenue, TTM
$302.80M
Revenue growth, YoY
+1696.0%
Net income, TTM
-$184.79M
Net margin
-61.0%
Free cash flow, TTM
-$141.82M
EPS, diluted, TTM
-$1.26
Cash
$218.87M
P/S
6.91
Market cap
$2.09B
Annual revenue$68.56M
FY2017FY2025
Annual net income-$437.99M
FY2017FY2025
Annual free cash flow-$396.61M
FY2017FY2025

VIR revenue and earnings growth

VIR revenueQ3 2026-$188.0K

FY YoY
-7.6%
5Y CAGR
-2.1%

VIR revenue was -$188.0K in fiscal Q3 2026 (ended Sep 30, 2026), compared with $240.0K a year earlier. For the full fiscal 2025 it was $68.56M, down 7.6% from fiscal 2024. Compound annual growth was -2.1% over 5 years. It rose in 4 of the last 8 fiscal years.

VIR net incomeQ3 2026-$96.25M

VIR net income was -$96.25M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$163.14M a year earlier. For the full fiscal 2025 it was -$437.99M, compared with -$521.96M in fiscal 2024.

VIR EPSQ3 2026-$0.57

VIR diluted EPS was -$0.57 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$1.17 a year earlier. For the full fiscal 2025 it was -$3.16, compared with -$3.83 in fiscal 2024.

VIR free cash flowQ3 2026-$106.11M

VIR free cash flow was -$106.11M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$167.89M a year earlier. For the full fiscal 2025 it was -$396.61M, compared with -$453.65M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue$68.56M$74.20M$86.18M$1.62B$1.10B$76.37M$8.09M$10.67M$2.71M
Cost of revenue$26.0K$845.0K$2.77M$146.32M$65.86M$0$0--
Gross profit$68.53M$73.36M$83.42M$1.47B$1.03B$76.37M$8.09M--
Research and development$455.97M$506.50M$579.72M$474.65M$448.01M$302.41M$148.47M$100.23M$62.51M
Selling, general and admin$92.07M$119.03M$174.44M$161.76M$160.79M$70.94M$37.60M$29.13M$21.69M
Operating income-$479.33M-$587.16M-$684.30M$833.07M$420.75M-$296.98M-$177.98M-$118.69M-$81.50M
Pre-tax income-$437.77M-$523.11M-$628.19M$754.28M$549.80M-$298.61M-$174.53M-$116.36M-$80.78M
Income tax$217.0K-$1.15M-$13.08M$238.44M$21.22M$54.0K$154.0K-$480.0K-$10.92M
Net income-$437.99M-$521.96M-$615.06M$515.84M$528.58M-$298.67M-$174.68M-$115.88M-$69.85M
EPS, basic-$3.16-$3.83-$4.59$3.89$4.07-$2.51-$5.76-$15.12-$32.45
EPS, diluted-$3.16-$3.83-$4.59$3.83$3.96-$2.51-$5.76-$15.12-$32.45
Diluted shares138.5M136.2M134.1M134.8M133.4M119.2M30.3M7.7M2.2M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Cash and equivalents$232.19M$318.69M$241.58M$867.97M$363.42M$451.49M$122.82M$59.36M$188.92M
Short-term investments$228.75M$678.05M$1.27B$1.52B$217.18M$300.29M$274.10M$50.84M-
Receivables---$0$773.08M$0---
Current assets$514.08M$1.04B$1.59B$2.52B$1.56B$772.37M$403.00M$117.78M-
Goodwill$16.94M$16.94M$16.94M$16.94M$16.94M$16.94M$16.94M$16.94M-
Total assets$1.00B$1.40B$1.92B$2.80B$1.95B$918.76M$512.07M$191.60M-
Current liabilities$92.81M$119.66M$175.41M$511.03M$341.24M$99.06M$59.21M$39.91M-
Total liabilities$237.55M$248.43M$328.82M$724.13M$522.42M$201.91M$88.13M$61.64M-
Shareholders' equity$765.28M$1.15B$1.59B$2.08B$1.43B$716.85M$423.94M-$179.18M-$68.92M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Operating cash flow-$391.78M-$446.35M-$778.78M$1.66B-$47.59M-$190.94M-$129.63M-$94.10M-$66.38M
Capital expenditures$4.83M$7.30M$21.57M$68.01M$21.82M$6.55M$8.94M$8.19M$2.74M
Free cash flow-$396.61M-$453.65M-$800.36M$1.60B-$69.41M-$197.49M-$138.57M-$102.29M-$69.12M
Investing cash flow$310.37M$499.37M$164.63M-$1.19B-$140.81M-$9.86M-$256.16M-$60.44M-$29.99M
Financing cash flow$3.79M$4.39M$7.48M$34.76M$100.33M$529.47M$449.24M$24.98M$271.18M
Stock-based compensation$49.07M$78.46M$111.32M$102.08M$83.78M$27.60M$8.72M$5.05M$4.78M
Depreciation and amortization$11.68M$14.56M$19.45M$6.78M$5.28M$4.40M$3.29M$1.62M$255.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue growth, YoY-7.6%-13.9%-94.7%47.5%1334.4%843.9%-24.2%293.9%-
Net income growth, YoY----2.4%-----
EPS growth, YoY----3.3%-----
Gross margin100.0%98.9%96.8%90.9%94.0%100.0%100.0%--
Operating margin-699.2%-791.3%-794.0%51.6%38.4%-388.9%-2199.7%-1112.6%-3009.5%
Net margin-638.9%-703.4%-713.7%31.9%48.3%-391.1%-2159.0%-1086.3%-2579.5%
Free cash flow margin-578.5%-611.4%-928.7%98.7%-6.3%-258.6%-1712.7%-958.8%-2552.5%
Return on equity-57.2%-45.4%-38.7%24.8%36.9%-41.7%-41.2%--
Return on assets-43.7%-37.3%-32.1%18.4%27.0%-32.5%-34.1%-60.5%-
Current ratio5.548.719.054.934.587.806.812.95-

Source: XBRL data Vir Biotechnology Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

VIR peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
VIR$302.80M+1696.0%-$184.79M-61.0%$2.09B
AMGN$38.90B+8.2%$9.39B24.1%$249.05B
GILD$30.99B+6.5%-$3.86B-12.5%$207.00B
MRNA$2.52B+13.1%-$2.79B-110.5%$101.48B
ARGX$4.25B+88.6%$1.29B30.4%$57.55B
RVMD$0--$1.13B-$41.59B
BIIB$10.30B+2.3%$347.50M3.4%$36.71B
BNTX€2.87B+4.3%-€1.14B-39.6%$21.98B
EXEL$2.50B+9.1%$885.14M35.5%$16.98B

VIR FAQ

8 questions
  • What is VIR revenue?
    Vir Biotechnology Inc. (VIR) reported $302.80M of revenue for the twelve months ended Sep 30, 2026. That is up 1696.0% from the year before. Revenue for fiscal 2025 was $68.56M.
  • Is VIR profitable?
    No. Vir Biotechnology Inc. reported a net loss of $184.79M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does VIR have?
    Vir Biotechnology Inc. reported $218.87M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is VIR revenue growing?
    Vir Biotechnology Inc.'s revenue changed -7.6% in fiscal 2025, to $68.56M. Its compound annual growth rate was -2.1% over 5 years.
  • What is VIR free cash flow?
    Vir Biotechnology Inc. generated -$141.82M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$141.02M less capital expenditures.
  • What is VIR earnings per share?
    Diluted earnings per share were -$1.26 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did VIR last report financial results?
    The latest statements here come from Vir Biotechnology Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.
  • Where does this VIR financial data come from?
    Quantisnow builds these statements from the structured XBRL data Vir Biotechnology Inc. files with the SEC. It is provided for information only and is not investment advice.